BIO 2019 - Tagged with Session Types>Breakout Sessions

Opioids: Changing the Paradigm on Treating Pain and Addiction

Addressing Barriers to Coverage and Access for Pain and Addiction Treatment: Where are We Now?

106AB, Level 100

Richard PopsChairman & CEO atAlkermes, Inc. Kimberly BrandtPrincipal Deputy Administrator for Operations atCenters for Medicare & Medicaid Services (CMS) Kathleen BroglioAssistant Professor of Medicine atGeisel School of Medicine at Dartmouth Justin Luke RileyPresident & CEO atYoung People in Recovery

Highly Prevalent Chronic Diseases

Addressing Unmet Need in Cardiovascular Disease

118B, Level 100

John GlasspoolCEO and Member, Board of Directors atAnthos Therapeutics Dr. Grace ColonCEO atInCarda Therapeutics Jonathan FreemanSenior Advisor atBlackstone Life Sciences Ms. Bray Patrick-LakeDirector of Stakeholder Engagement atDuke Clinical Research Institute Dr. Eric David PetersonProfessor of Medicine atFred Cobb David SoergelGlobal Head of Cardiometabolic Development atNovartis

Highly Prevalent Chronic Diseases

Addressing Unmet Need in Depression

118B, Level 100

Lauren MartzAssociate Editor atBiocentury PHYLLIS FOXWORTHAdvocacy Vice President atDepression and Bipolar Support Alliance David HoughEsketamine Compound Development Team Leader atJanssen Pharmaceutical Companies of Johnson & Johnson Ekaterina MalievskaiaHead of Research & Development and Co-Founder atCOMPASS Mr. Andrew SperlingDirector of Legislative Advocacy atNational Alliance on Mental Illness (NAMI)

Highly Prevalent Chronic Diseases

Addressing Unmet Need in Diabetes/Obesity

118B, Level 100

Danielle MarraAssociate Principal atCello Health BioConsulting (Previously Defined Health) Brian BloomquistDiabetes External Innovation atEli Lilly and Company Tomas LandhInnovation Sourcing Vice President, Senior Principal Scientist R&D External Innovation Sourcing atNovo Nordisk A/S Denmark Andrew ReaumePresident & CEO atMelior Pharmaceuticals

Infectious Disease and Vaccines

Advances in HIV Treatment and Prevention

115C, Level 100

Swati GuptaVice President, Research Integration & Innovation atInternational AIDS Vaccine Initiative Daria HazudaVice-President and Therapeutic Area Head, Infectious Disease And Vaccines, CSO, Merck Cambridge Exploratory Science Center, Merck Research Labs atMerck Dr. Gary NabelChief Scientific Officer, Global Research and Development, and Head of the North American R&D Hub atSanofi Frank Tomaka, MDSenior Director, Franchise Clinical Leader/HIV & STI Vaccines atJanssen Research & Development/Johnson & Johnson

Value‚ Patient Access and Reimbursement

After Trump’s Drug Pricing Blueprint: What Happens Next? A View from Washington

111AB, Level 100

Mr. Daniel ToddPrincipal atTodd Strategy

Brain Health

A New Era: AI-Based Precision Medicine & Neurological Disorders

116, Level 100

Kate SheridanLife Sciences and Biotech Reporter atSTAT News Mark Frasier, Ph.D.Senior Vice President, Research Programs atThe Michael J. Fox Foundation for Parkinson's Research Dr. Iya KhalilChief Commercial Officer and Co-Founder atGNS Healthcare Dr. Vaibhav NarayanVP and Head, Data Science and Digital Health Solutions, Neuroscience Therapeutic Area atJanssen: Pharmaceutical Companies of Johnson & Johnson

Translational Research

Anti-Aging Therapies: Taking Action to Increase the Human Healthspan

112AB, Level 100

Ms. Laura DemingFounder, Managing Partner atThe Longevity VC Dr. Tom HughesCEO atNavitor Pharmaceuticals Keith LeonardCEO atUnity Biotechnology Chen SchorCEO atresTORbio

Brain Health

Beyond Dementia: The REALLY Big Opportunities in Neuroscience

116, Level 100

Ms. Kimberly HaCEO atKKH Advisors Dr. Mylea CharvatCEO & Founder atSavonix Dr. Michael HillProfessor of Neurology atUniversity of Calgary Dr. Michael TymianskiPresident and CEO atNoNO Inc. Dianna WillisAssociate Director atBurke Neurological Institute

Digital Health

Bitcoin Your Data! From Trusted Pharma Silos to Trustless Community-Owned Blockchain-Based Precision Medicine Data Trials

104AB, Level 100

Sanjeev WadhwaChief Executive Officer atLife Singularity, Inc. James CanterburyPrincipal atEY John KamaraDirector atGlobal Gaming Africa Dr. David KoepsellCEO atEncrypgen Katherine KuzmeskasCEO atSimplyVitalHealth.com Kamal ObbadCEO atNebula Genomics

Business Development and Finance

Blazing a Trail: Lessons on Bringing a New Technology to Market

109AB, Level 100

Peter HennesseyPartner atBallard Spahr LLP Joseph La BargeChief Legal Officer atSpark Therapeutics Frank LeonardSVP Corporate Strategy and Health Policy atNovocure

Emerging Opportunities in Global Markets

Brexit and the Impact on the Biotechnology Industry

115B, Level 100

Mr. Steve BatesCEO atBioIndustry Association Edwin BealeVP Business Development atMaSTherCell Global Leonor EnesScientific Officer atEuropean Medicines Agency Bernard GrimmHealthcare Director atEuropaBio Mrs. Tineke Van hoolandChairwoman atBIO.BE

Regulatory Innovation

Building a Brighter Future for Children: How Will Large Pediatric Trial Networks Help Deliver Safe, Effective Medicines?

111AB, Level 100

Dr. Pierre MeulienExecutive Director atInnovative Medicines Initiative Gerri BaerMedical Officer, Neonatology Team Leader atU.S. Food and Drug Administration Dr. Annette BakkerPresident atChildren’s Tumor Foundation Dr. Sam MaldonadoVice President, Head of Child Health Innovation and Leadership Department (CHILD) atJohnson & Johnson

Business Development and Finance

Building a Winning Team for Biotech Business Success – Lessons You Can Learn from Industry Veterans and Former NFL Player Turned Broadcaster Solomon Wilcots

107AB, Level 100

Solomon WilcotsSports broadcaster and Sports-Health Alliance Leader atSirius XM Inc.; Russo Partners, LLC; Sky Sports UK Raza BokhariCo-Chairman and Interim CEO atFSD Pharma Mei Mei HuChief Executive Officer atUnited Neuroscience Ltd. William NewellChief Executive Officer and Director atSutro Biopharma Inc. Gil Van BokkelenChairman and CEO atAthersys

Biofuels and Renewable Chemicals

CANCELLED Nutrition and Wellness From Industrial Biotech Innovation

110AB, Level 100

Emerging Opportunities in Global Markets

CANCELLED Real World Evidence: What Role can it Play in Assessing the Value of Innovative Medicines in Europe?

115A, Level 100

Marie Helene FandelDirector atAmgen Dr. Alexander NatzSecretary General atEuropean Confederation of Pharmaceutical Entrepreneurs (Belgium) Tania TeixeiraEMA Liaison Official at FDA, International Affairs Division atEuropean Medicines Agency

Genome Editing

Can Genome Editing Fulfill Its Promise and Meet Unmet Medical Needs?

118A, Level 100

Dr. Eric KmiecDirector, Gene Editing Institute atChristiana Care Health System Jonathan MarronPediatric Oncologist, Bioethicist, Health Services Researcher atDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School Dr. Debra MathewsAssoc Professor atJohns Hopkins School of Medicine Giorgio SirugoAdjunct Associate Professor of Medicine atUniversity of Pennsylvania School of Medicine

Business Development and Finance

Changing the Game: Breaking Down Barriers and Building Up the Next Generation

107AB, Level 100

Mrs. Rachel KingCo-Founder and CEO atGlycoMimetics Lily CorteseDirector, Transactions atJohnson & Johnson Arpa GarayPresident of Global Pharma atMerck Monique Kelley GigliottiDirector, R&D Communications atTakeda Pharmaceutical Company, Ltd. Ms. Nancy SimonianFounding CEO atSyros

Oncology

Climbing Cancer’s North Face: The Challenges of Developing and Clinically Validating Biomarkers for Early Cancer Detection

105AB, Level 100

Dr. Moira GunnJournalist & Professor atTech Nation Media Dr. Wendy AldertonCancer Research UK Cambridge Centre Early Detection Programme Manager atCambridge University, UK Dr. Mike FisherCommercial Director atOncimmune Duncan WhitneyHead, Early Detection Lung Cancer Initiative atJohnson & Johnson

Personalized Medicine and Diagnostics

Clinical and Economic Value of Personalized Cancer Treatment

116, Level 100

Dr. Daryl PritchardSenior Vice President, Science Policy atPersonalized Medicine Coalition Neal MeropolVice President, Research Oncology atFlatiron Health Mr. Ammar QadanVP Global Market Access atIllumina Dr. Michael ShermanChief Medical Officer & Senior Vice President atHarvard Pilgrim Health Care Lotte SteutenVice President and Head of Consulting atOffice of Health Economics, London, UK